Between GBM-associated antigen-targeting CD4+ and CD8+ CAR-T cells, CD4+ CAR T cells showed effector persistency after tumor challenge and similarly in orthotopic GBM model, CD4+ CAR-T outcompeted CD8+ CAR-T in terms of durable anti-tumor response (232). This evidence concerns the gene CD4 and neoplasm.